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Abstract
Background: Drug discovery and chemical biology are exceedingly complex and demanding
enterprises. In recent years there are been increasing awareness about the importance of
predicting/optimizing the absorption, distribution, metabolism, excretion and toxicity (ADMET)
properties of small chemical compounds along the search process rather than at the final stages.
Fast methods for evaluating ADMET properties of small molecules often involve applying a set of
simple empirical rules (educated guesses) and as such, compound collections' property profiling can
be performed in silico. Clearly, these rules cannot assess the full complexity of the human body but
can provide valuable information and assist decision-making.
Results: This paper presents FAF-Drugs2, a free adaptable tool for ADMET filtering of electronic
compound collections. FAF-Drugs2 is a command line utility program (e.g., written in Python)
based on the open source chemistry toolkit OpenBabel, which performs various physicochemical
calculations, identifies key functional groups, some toxic and unstable molecules/functional groups.
In addition to filtered collections, FAF-Drugs2 can provide, via Gnuplot, several distribution
diagrams of major physicochemical properties of the screened compound libraries.
Conclusion: We have developed FAF-Drugs2 to facilitate compound collection preparation, prior
to (or after) experimental screening or virtual screening computations. Users can select to apply
various filtering thresholds and add rules as needed for a given project. As it stands, FAF-Drugs2
implements numerous filtering rules (23 physicochemical rules and 204 substructure searching
rules) that can be easily tuned.
Background
Hit/lead compounds can be identified either through
high-(medium) throughput screening approaches and/or
using virtual screening computations. In all situations, a
compound collection is screened with the goal of finding
molecules that could enter the drug discovery process or
that could help to explore molecular mechanisms,
unravel new molecular functions and deorphanize puta-
tive targets. Yet, it is well documented that to avoid costly
failures in screening projects, ADMET (Absorption, Distri-
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should be considered at an early stage [1-3]. In general,
molecules with inadequate properties, even if they do not
fail in clinical trials, usually increase the development
costs and put significant burden on patients, since, for
instance, poorly absorbed drugs have to be given at a
higher dose or shifted from oral to intravenous route. A
compound collection may be prepared for a chemical
biology project or for drug discovery, and in these cases,
one may need molecules with a more "lead-like" or "drug-
like" profile [3-5]. Experimental ADMET measurements
allow to investigate several mechanisms, from crossing
physiological barriers, group reactivity to metabolism.
Different experimental assays have been developed over
the years to try to assess/predict ADMET properties, but in
silico computations can also be carried out to rapidly ana-
lyze a compound collection or prior to synthesis. In gen-
eral, these calculations provide valuable information that
can then be further investigated experimentally [6].
The fastest method for evaluating the drug-like or lead-
like properties of a compound is to apply simple rules that
characterize the molecule. Well-known rules are, for
instance, the so-called "rule of 5" (RO5) [7]. These rules
are a set of property values that were derived from classi-
fying the key physicochemical properties of drug com-
pounds. Drug-like molecules, according to Dr. Lipinski,
refers to compounds that have sufficiently acceptable
ADME properties and sufficiently acceptable toxicity
properties to survive through the completion of human
Phase I clinical trial. Yet, the rule of 5 only underlines
properties that would make a compound a likely orally
active drug in humans, but clearly these rules do not
investigate directly metabolism, probe if a molecule is a
frequent hitter or if it contains reactive functional groups.
Over the years, many additional rules have thus been pro-
posed [8,9] and can be smartly combined with the "rule
of 5". Several outstanding commercial packages from
ChemAxon, OpenEye or the Chemical Computing Group
have been developed and can be used to perform this kind
of filtering. To this end, each compound can be associated
with a series of descriptors deduced from its 1D/2D/3D
structures while some specific substructures and physico-
chemical properties can also be investigated.
In this article, we describe a new enhanced version of FAF-
Drugs, which was originally based on the free chemoin-
formatics toolkit Frowns [10]. The first FAF-Drugs version
could only be called online to filter out libraries using a
simple set of 14 structural and physicochemical rules. The
new (Additional file 1) FAF-Drugs2 version has been
entirely rewritten in Python, does not use Frowns (i.e., the
chemistry toolkit is no longer maintained) but imports
modules from the OpenBabel toolkit. In its current ver-
sion, FAF-Drugs2 still provides the basic physicochemical
rules computed in the previous version, but it now has
many additional features. For instance, it allows selection
based upon the number of heavy atoms, search for toxic
or undesirable substructures, and permit to flag oral bioa-
vailability using Lipinski's [7], Veber's [8] and Egan's [11]
rules. With regard to substructure search, we, for the time
being, aim at identifying key toxic functional groups and
some toxic and unstable molecules (or groups). We detect
22 "warhead" chelators [12,13], 15 frequent hitters [14],
48 promiscuous inhibitors [15,16] and 116 other key
functional groups [17-19]. The package can now be down-
loaded and users can install it on their workstations and
implement new rules as needed.
Implementation
FAF-Drugs2 consists of a set of object oriented Python
modules, some of them importing methods from the
OpenBabel toolkit. This is made possible through the
OpenBabel Python module Pybel that provides to "FAF-
Drugs2" access to the OpenBabel C++ library [20].
There are several reasons why we chose to design the soft-
ware using Python programmable scripting language and
the OpenBabel chemoinformatics toolkit. Python is
widely used in the scientific community and as such FAF-
Drugs2 was developed to be user friendly for the scien-
tists. Furthermore, Python can easily connect external
modules written in other languages, hence using facilities
of the OpenBabel toolkit. Actually, OpenBabel is a C++
toolkit [21], designed to read, convert, write and dissect
molecular files as well as to compute/predict some useful
descriptors such as logP values, molecular weight while
allowing SMARTS substructure search through implemen-
tation of the SMARTS language [22]. Moreover all func-
tionalities can be accessed, imported and integrated in our
toolkit by using the Pybel module [20]. We indeed aim at
providing a free, collaborative and customizable software
that could evolve as knowledge and awareness about
ADMET increase.
In order to generate a compound collection with accepta-
ble physicochemical properties, several filtering rules are
applied, including the well-known Lipinski's rule-of-five
(poor oral absorption if the molecular weight is more
than 500, logP or octanol/water partition coefficient must
not be more than 5, H-bond donors must not be more
than 5 and H-bond acceptors must not be more than 10)
[7]. The main properties computed by FAF-Drugs2 are: the
number of rigid and flexible bonds [8], TPSA (topological
Polar Surface Area) value according to Ertl et al[23], the
number and maximum size of system rings, and the pres-
ence of unwanted chemicals or chemical substructures
(i.e., carried out using SMARTS searches).Page 2 of 9
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The top-level objects and modules of FAF-Drugs2 are
illustrated in Figure 1. Briefly, the architecture of the pro-
gram is as follow:
Scanner
Performs parsing of the parameter files, writing of the out-
put files and removing of duplicate molecules. Further-
more, if the compound libraries contain salts and
counterions, this module applies the desalt utility of
Pybel.
CreateMol
Creates molecular objects ready to be filtered.
Rules
Defines all the filtering rules. This module computes the
following descriptors:
A) Directly computed or predicted by using OpenBabel
abilities:
(1) Molecular weight (part of Lipinski's RO5).
(2) Number of rotatable bonds.
Defined as any single non-ring bond, bounded to non-ter-
minal heavy atoms according to Veber et al [8]. The amide
O = C-N bonds are not considered because of their high
rotational energy barrier.
(3) Number of rigid bonds.
(4) Number of heavy atoms.
(5) Number of atom with a net charge.
(6) Sum of formal charges.
(7) Number of carbon atoms (c), (8) number of hetero-
atoms (het), (9) Value of ratio het/c.
(10) Specific atoms which are undesirable.
(11,12,13,14) SMARTS substructure searching for func-
tional groups and undesirable molecules:
(a) Reactive or undesirable functional groups according to
Rishton et al and Oprea et al. [9,12,13]
(b) Promiscuous inhibitors according to McGovern et al.
[24] and Seidler et al. [16]
(c) Frequent hitters compounds according to Roche et al.
[14]
(d) Other functional groups according to Sirois et al. [17]
(15) log P (part of Lipinski's RO5).
For small collections, the logP value is computed by
OpenBabel according to Wildman et al. [20,25]. If the col-
lection is larger than 10,000 molecules, logP should be
predicted through the X-Score package (freely available
through a license agreement after registration, informa-
tion can be found at http://sw16.im.med.umich.edu/soft
ware/xtool/), in this case XlogP values are computed as
described in [26].
(16,17) Numbers of Hydrogen bond donors and hydro-
gen bond acceptors (part of Lipinski's RO5), computed by
using SMARTS expression.
B) Other descriptors computed by using in house Python
methods.
(18) Topological Polar Surface Area (TPSA) according to
the method developed by Ertl et al. [23].
(19) Number of rings and (20) maximum size of ring,
computed by using in house methods from the GetRings
module.
(21) Number of violations of Lipinski's RO5 according to
Lipinski et al. [7].
(22) Veber Rule: defined as TPSA>140Å or number of
rotatable bonds>10 [8].
(23) Egan Rule: defined as TPSA > 131.6Å or log P > 5.88
[11].
SmartsCodes
Contains SMARTS patterns for detection of hydrogen
bond donors, hydrogen bond acceptors and all SMARTS
patterns for functional groups and undesirable molecules.
GetRings
Contains all functions dedicated to identify the smallest
ring systems and the maximum size of rings.
FAFDrugs2
This is the main module of FAF-Drugs2. It manages mol-
ecule through creation of objects, filters the compounds
and deals with input and output.
Data sets and program parameters
Compound libraries must be in a standard SDFile format
[27]. Before running FAF-Drugs2, users should edit and
check two parameter files named, faf2.param and
groups.param. The first one, faf2.param, contains, amongPage 3 of 9
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Schematic diagram of the FAF-Drugs2 package architectureFigure 1
Schematic diagram of the FAF-Drugs2 package architecture. FAF-Drugs2 requires as input files a compound collec-
tion in SDF format and two parameter files, one containing physicochemical thresholds and the other, the list of substructures 
that have to be investigated. Several output files are generated, among others, one containing the molecules that do pass the fil-
ters and another one, the molecules that do not pass the test. In addition, a table file reporting all the computed values/descrip-
tors for each compound is provided (see text for explanations).
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BMC Bioinformatics 2008, 9:396 http://www.biomedcentral.com/1471-2105/9/396others, the input file location, the path to X-Score execut-
able file if needed, and all the physicochemical threshold
values. The second one, groups.param, contains filtering
rule thresholds for detection of functional groups and for
undesirable compounds/groups (e.g., Michael acceptors,
nitro or aldehyde).
Results
FAF-Drugs2 is a computer tool (Fig. 1) that helps prepar-
ing compound collections. In order to give an example of
how to apply this package, we decided to process a large
compound collection, namely the June 2008 ChemBridge
EXPRESS-Pick™ Database, and provide the key output
data obtained by FAF-Drugs2 [28]. This ChemBridge
library contains 457,761 compounds. We performed tests
on a Linux machine (Dell Precision 690, Bi-Xeon 3 Ghz
processors, 2 GB DDRAM, running the CentOS 5 operat-
ing system) with the default parameter files. The general
properties for this collection (which does not contain any
duplicate) as computed by FAF-Drugs2 indicates, among
others, that 3,56 % (16315) of the molecules are associ-
ated with salts/counterions. Further, figure 2 displays the
distribution of the main physico-chemical descriptors for
the EXPRESS-Pick™ Database. According to these descrip-
tors, we observed that, 1.98 % (9077) of the molecules
have molecular weight over 500, 10,65 % (48769) of the
molecules have a XLogP value over 5, 0.02 % (85) of the
molecules have more than 5 H-Bond donors, 0.04 %
(179) of the molecules have more than 10 H-Bond accep-
tors, 1,74 % (7950) of the molecules have TPSA value over
150, 0.9 % (3978) of the molecules have more than 10
rotatable bonds and finally 0.03% (181) of the molecules
contain more than 5 system rings.
Along the same line of reasoning, we illustrate the way
FAF-Drugs2 deals with some functional groups (Fig. 3).
For example, nitro derivatives have been reported to be
hepatocarcinogens [29] and nitroaromatics are reduced to
form reactive, nitroanion radical, nitroso intermediate,
and N-hydroxy derivative [30]. These reactive metabolites
are usually not welcome in drug discovery projects and
molecules containing nitroaromatic groups are in general
removed from a compound collection or the group will
have to be modified later on with another electronwith-
drawing group such as trifluoromethyl by chemical syn-
thesis. Yet, it is important to note that some marketed
drugs display such a group, like the benzodiazepines,
nitrazepam and flunitrazepam and the anti-androgens
flutamide and nilutamide [31], among others. When
investigating the ChemBridge collection for the presence
of nitro groups, we found 48801 molecules (10.8%) con-
taining at least one occurrence of this chemical function.
Also, although a few hydrazinic drugs are used, this group
has been regularly associated with hepatoxicity and car-
cinogenesis [32]. We found 5996 molecules (1.31%) that
contain at least one hydrazine group.
Furthermore, some simple compounds can have dramatic
effects on Human, for instance some molecules are well
known to be carcinogens [33]. For example, aniline or
arylamine, a simple aromatic amine, is toxic by inhalation
and absorption. This group is regularly pointed out as able
to generate toxic metabolites. In addition, some polymor-
phisms in the N-acetyltransferase 1 (NAT1, one of the
major hepatic phase II enzymes) are associated with
rapid/slow acetylation phenotypes with altered formation
of acetylamino metabolites and increased susceptibility to
cancers [34]. However, the arylamine moieties are part of
drugs like tacrine and sulfamethoxazole where, in several
cases, the amino group has been linked with the hepato-
toxity of these drugs [35,36]. We found 232447 (50.8%)
compounds in the ChemBridge collection containing one
aniline group.
Also, the number of occurrences of some chemical groups
could impede the development of molecules that have to
be given through oral route. For instance, it is often con-
sidered that the number of occurrence of OH groups
should not be over 4 or 5 or 6 [37]. It is expected that such
polyhydroxylated molecules display poor bioavailability,
which is probably a consequence of their rapid metabolic
transformation in the liver and gastrointestinal tract [38].
Indeed, we ran FAF-Drugs2 on 4567 drug compounds
available at DrugBank [39,40] (small molecule drugs, July
2008, 171 duplicates seem to be present in this library)
and found that 501 molecules have more than 3 OH
groups and only 144 molecules have more than 5 OH
groups. We also carried out this investigation over the
ChemBridge collection and we found that 63 compounds
(0.01%) possess more than 3 hydroxyl groups.
Discussion
Drug discovery is an interdisciplinary, expensive and
time-consuming process and chemical biology projects
share a lot of the difficulties seen in drug discovery pro-
grammes. Advances in computational techniques and
hardware solutions have enabled in silico methods, and
in particular virtual screening, to speed-up modern hit
identification and optimization. In most cases, it seems
beneficial to run in silico ADMET prediction prior to or
after initial screening experiments. Numerous observa-
tions over drug compounds have been made over the
years leading to a set of rules that can be applied to a com-
pound library or list of molecules, assuming one has
appropriate computer methods to parse and dissect each
molecule. The structure/atomic composition determine
some of the compound's properties. Interaction of the
structural properties of a molecule with its physical envi-
ronment cause physicochemical properties that can bePage 5 of 9
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Analysis of the main physicochemical properties of compound from the ChemBridge EXPRESS-Pick™ DatabaseFigure 2
Analysis of the main physicochemical properties of compound from the ChemBridge EXPRESS-Pick™ Data-
base. Physicochemical profile of the ChemBridge molecules as computed by FAF-Drugs2.
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BMC Bioinformatics 2008, 9:396 http://www.biomedcentral.com/1471-2105/9/396measured experimentally or estimated in silico. Interac-
tions of the structural properties of compounds with mol-
ecules/enzymes cause biochemical properties such as
metabolism. Ultimately, when the physicochemical and
the biochemical properties interact with a living system
they can cause toxicity [41]. From these remarks, it is obvi-
ous that simple rules cannot fully estimate pharmacoki-
netics (e.g., half life, clearance...) nor toxicity, yet,
investigations of fundamental physicochemical and/or
simple biochemical properties together with structure and
substructure analyses provide valuable information and
allows for the in silico filtering of a compound collection.
In the present study we present an ADMET filtering pack-
age, called FAF-Drugs2, written in Python, which can help
preparing a compound collection. The library is loaded
into the engine as a SDF file and the program, together
with two user-defined parameter files, outputs a "non-
toxic file" and a "toxic file" that contain respectively, com-
pounds that do pass the filters and compounds that do
not satisfy the rules. In addition, the program writes, in a
table format, a full report called "table.results", a report of
the substructure search called "groups.table" and a file
called "summary.txt" summarizing information about
each compound. Finally, the users can have the program
plot some of the main physicochemical properties to facil-
itate graphical analysis of the library. The FAF-Drugs2
package can easily be tuned according to a given project.
It has been tested successfully on several libraries (not
shown) including the ChemBridge compound collection.
Conclusion
We have developed the FAF-Drugs2 package to facilitate
compound collection preparation. Users can select to
apply various filtering thresholds and add rules as needed.
This application is suitable for conducting filtering of
large compound collections and run on Linux platforms.
The FAF-Drugs2 package is freely available.
Examples of undesirable substructures/functional groups assessed by FAF-Drugs2Figure 3
Examples of undesirable substructures/functional groups assessed by FAF-Drugs2. Many functional groups/mole-
cules can be problematic for drug discovery projects. Here we illustrate this point with three undesirable groups/compounds 
searched by FAF-Drugs2 (see Text for details).Page 7 of 9
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• Project name: FAF-Drugs2
• Project home page: http://www.vls3d.com/FAF2/
FAFDrugs2.tar.gz
• Operating system(s): Linux
• Programming language: Python
• Other requirements: Python 2.5.1 or higher, OpenBa-
bel 2.1.1, GnuPlot 4.2.3 (optional), X-Score (optional).
• License: GNU GPL
• Any restrictions to use by non-academics: None
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